Karin C D Van Der Rijt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/476646/publications.pdf

Version: 2024-02-01

87 papers 3,069 citations

147801 31 h-index 53 g-index

89 all docs 89 docs citations

89 times ranked

3352 citing authors

#	Article	IF	CITATIONS
1	Predictors of Mortality in Patients with Advanced Cancer—A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 328.	3.7	10
2	The development of the ADO-SQ model to predict 1-year mortality in patients with COPD. Palliative Medicine, 2022, 36, 821-829.	3.1	2
3	Decisional Conflict after Deciding on Potential Participation in Early Phase Clinical Cancer Trials: Dependent on Global Health Status, Satisfaction with Communication, and Timing. Cancers, 2022, 14, 1500.	3.7	О
4	Predictors of mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulmonary Medicine, 2022, 22, 125.	2.0	7
5	Evaluation of centers for information and support combining formal and informal care for patients with cancer: a systematic review of the literature. Supportive Care in Cancer, 2022, 30, 7079-7098.	2.2	9
6	Quality of Life and Quality of Death outcomes of the SILENCE study. Journal of Pain and Symptom Management, 2022, , .	1.2	0
7	Hydration and symptoms in the last days of life. BMJ Supportive and Palliative Care, 2021, 11, 335-343.	1.6	31
8	The Value of the Surprise Question to Predict One-Year Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study. Respiration, 2021, 100, 780-785.	2.6	9
9	Physicians' views on the usefulness and feasibility of identifying and disclosing patients' last phase of life: a focus group study. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2020-002764.	1.6	7
10	Advance Care Planning in Asia: A Systematic Narrative Review of Healthcare Professionals' Knowledge, Attitude, and Experience. Journal of the American Medical Directors Association, 2021, 22, 349.e1-349.e28.	2.5	59
11	Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain. Cancers, 2021, 13, 2768.	3.7	4
12	Identifying patient values impacting the decision whether to participate in early phase clinical cancer trials: A systematic review. Cancer Treatment Reviews, 2021, 98, 102217.	7.7	6
13	Asian patients' perspectives on advance care planning: A mixed-method systematic review and conceptual framework. Palliative Medicine, 2021, 35, 1776-1792.	3.1	33
14	Effects of Implementation of a Standardized Palliative Care Pathway for Patients with Advanced Cancer in a Hospital: A Prospective Pre- and Postintervention Study. Journal of Pain and Symptom Management, 2021, 62, 451-459.	1.2	7
15	Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of Life. JAMA - Journal of the American Medical Association, 2021, 326, 1268.	7.4	24
16	Reflections on Including Patients in a Randomized Placebo-Controlled Multicentre Trial in the Dying Phase – the SILENCE Study. Journal of Pain and Symptom Management, 2021, , .	1.2	0
17	Validation of the Dutch Version of the Breakthrough Pain Assessment Tool in Patients With Cancer. Journal of Pain and Symptom Management, 2020, 59, 709-716.e2.	1.2	4
18	Understanding relatives' experience of death rattle. BMC Psychology, 2020, 8, 62.	2.1	6

#	Article	IF	Citations
19	Response to "Hyoscine Butylbromide for the Management of Death Rattle: Sooner Rather Than Later― Journal of Pain and Symptom Management, 2019, 57, e1-e2.	1.2	1
20	Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT). BMC Palliative Care, 2019, 18, 106.	1.8	9
21	Medication Discontinuation at the End of Life: A Questionnaire Study on Physicians' Experiences and Opinions. Journal of Palliative Medicine, 2018, 21, 1166-1170.	1.1	11
22	Interventions in hospitalised patients with cancer: the importance of impending death awareness. BMJ Supportive and Palliative Care, 2018, 8, 278-281.	1.6	7
23	Identifying the subtypes of cancer-related fatigue: results from the population-based PROFILES registry. Journal of Cancer Survivorship, 2018, 12, 38-46.	2.9	31
24	Development and feasibility of a web application to monitor patients' cancer-related pain. Supportive Care in Cancer, 2018, 26, 635-642.	2.2	26
25	Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy. Cancers, 2018, 10, 445.	3.7	2
26	Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients. European Journal of Cancer, 2018, 105, 79-87.	2.8	10
27	Scopolaminebutyl given prophylactically for death rattle: study protocol of a randomized double-blind placebo-controlled trial in a frail patient population (the SILENCE study). BMC Palliative Care, 2018, 17, 105.	1.8	11
28	Palliative care team consultation and quality of death and dying in a university hospital: A secondary analysis of a prospective study. PLoS ONE, 2018, 13, e0201191.	2.5	23
29	Effects of smoking and body mass index on the exposure of fentanyl in patients with cancer. PLoS ONE, 2018, 13, e0198289.	2.5	3
30	Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl. Oncotarget, 2018, 9, 18269-18276.	1.8	5
31	A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. Clinical Pharmacokinetics, 2017, 56, 733-746.	3.5	13
32	Feasibility of assessing patients' acceptable pain in a randomized controlled trial on a patient pain education program. Palliative Medicine, 2017, 31, 553-558.	3.1	9
33	Is there a role for pharmacogenetics in the dosing of fentanyl?. Pharmacogenomics, 2017, 18, 417-419.	1.3	6
34	Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis. Oncology, 2017, 93, 323-328.	1.9	0
35	Adherence to Analgesics in Oncology Outpatients: Focus on Taking Analgesics on Time. Pain Practice, 2017, 17, 616-624.	1.9	16
36	A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. British Journal of Clinical Pharmacology, 2017, 83, 294-313.	2.4	80

#	Article	IF	CITATIONS
37	Physician-Reported Symptoms and Interventions in People with Intellectual Disabilities Approaching End of Life. Journal of Palliative Medicine, 2016, 19, 1142-1147.	1.1	13
38	Effect of palliative care nurse champions on the quality of dying in the hospital according to bereaved relatives: A controlled before-and-after study. Palliative Medicine, 2016, 30, 180-188.	3.1	21
39	Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients. European Journal of Clinical Pharmacology, 2016, 72, 459-467.	1.9	21
40	A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures. Journal of Pain, 2015, 16, 935-946.	1.4	56
41	Dying in the Hospital: What Happens and What Matters, According to Bereaved Relatives. Journal of Pain and Symptom Management, 2015, 49, 203-213.	1.2	40
42	Problems and Needs in Patients With Incurable Esophageal and Pancreaticobiliary Cancer. Gastroenterology Nursing, 2015, 38, 42-54.	0.4	5
43	Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. Journal of Neuro-Oncology, 2015, 121, 365-372.	2.9	31
44	Is Physician Awareness of Impending Death in Hospital Related to Better Communication and Medical Care?. Journal of Palliative Medicine, 2014, 17, 1238-1243.	1.1	7
45	Prevalence, Impact, and Treatment of Death Rattle: A Systematic Review. Journal of Pain and Symptom Management, 2014, 47, 105-122.	1.2	81
46	Nurse-Led Follow-Up at Home vs. Conventional Medical Outpatient Clinic Follow-Up in Patients With Incurable Upper Gastrointestinal Cancer: A Randomized Study. Journal of Pain and Symptom Management, 2014, 47, 518-530.	1.2	27
47	Fentanyl exposure after subcutaneous and transdermal administration: Results from a population pharmacokinetic study in cancer patients Journal of Clinical Oncology, 2014, 32, 9540-9540.	1.6	1
48	Improving the quality of palliative and terminal care in the hospital by a network of palliative care nurse champions: the study protocol of the PalTeC-H project. BMC Health Services Research, 2013, 13, 115.	2.2	20
49	The Evidence for Pharmacologic Treatment of Neuropathic Cancer Pain: Beneficial and Adverse Effects. Journal of Pain and Symptom Management, 2013, 46, 581-590.e1.	1.2	54
50	Cut Points on 0–10 Numeric Rating Scales for Symptoms Included in the Edmonton Symptom Assessment Scale in Cancer Patients: A Systematic Review. Journal of Pain and Symptom Management, 2013, 45, 1083-1093.	1.2	202
51	Systematic Monitoring and Treatment of Physical Symptoms to Alleviate Fatigue in Patients With Advanced Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 2013, 31, 716-723.	1.6	80
52	Can You Help Me Feel Less Exhausted All the Time?. Journal of Clinical Oncology, 2013, 31, 3056-3060.	1.6	5
53	Validation of the rotterdam MOVE2PC questionnaire for assessment of nurses' knowledge and opinions on palliative care. Research in Nursing and Health, 2013, 36, 512-523.	1.6	16
54	Differences in Fatigue Experiences Among Patients With Advanced Cancer, Cancer Survivors, and the General Population. Journal of Pain and Symptom Management, 2012, 44, 823-830.	1.2	34

#	Article	IF	CITATIONS
55	Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors. Cancer, 2012, 118, 6005-6011.	4.1	57
56	Dose dense 1Âweek on/1Âweek off temozolomide in recurrent glioma: a retrospective study. Journal of Neuro-Oncology, 2012, 108, 195-200.	2.9	34
57	Awareness of dying: it needs words. Supportive Care in Cancer, 2012, 20, 1227-1233.	2.2	34
58	Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids. Supportive Care in Cancer, 2012, 20, 1639-1647.	2.2	10
59	A combined pain consultation and pain education program decreases average and current pain and decreases interference in daily life by pain in oncology outpatients: A randomized controlled trial. Pain, 2011, 152, 2632-2639.	4.2	41
60	Survey on the Prevalence of Pain in Dutch District Nursing Care. Journal of Palliative Medicine, 2011, 14, 696-699.	1.1	4
61	Effectiveness of a multidisciplinary consultation team for cancer pain and palliative care in a large university hospital in the Netherlands. BMJ Supportive and Palliative Care, 2011, 1, 322-328.	1.6	9
62	Clinical priorities, barriers and solutions in end-of-life cancer care research across Europe. Report from a workshop. European Journal of Cancer, 2010, 46, 1815-1822.	2.8	37
63	Exploration of Concerns of Relatives During Continuous Palliative Sedation of Their Family Members with Cancer. Journal of Pain and Symptom Management, 2009, 38, 452-459.	1.2	33
64	A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: A critical appraisal. European Journal of Cancer, 2009, 45, 1370-1380.	2.8	217
65	Pain prevalence and characteristics in three Dutch residential homes. European Journal of Pain, 2008, 12, 910-916.	2.8	59
66	Palliative Sedation in a Specialized Unit for Acute Palliative Care in a Cancer Hospital: Comparing Patients Dying With and Without Palliative Sedation. Journal of Pain and Symptom Management, 2008, 36, 228-234.	1.2	106
67	Using the LCP: Bereaved Relatives' Assessments of Communication and Bereavement. American Journal of Hospice and Palliative Medicine, 2008, 25, 207-214.	1.4	45
68	The effect of the Liverpool Care Pathway for the dying: a multi-centre study. Palliative Medicine, 2008, 22, 145-151.	3.1	122
69	Patient evaluation of end-of-life care. Palliative Medicine, 2007, 21, 243-248.	3.1	22
70	Changes in and correlates of individual quality of life in advanced cancer patients admitted to an academic unit for palliative care. Palliative Medicine, 2007, 21, 199-205.	3.1	21
71	Prognostic Value of Health-Related Quality-of-Life Data in Predicting Survival in Patients With Anaplastic Oligodendrogliomas, From a Phase III EORTC Brain Cancer Group Study. Journal of Clinical Oncology, 2007, 25, 5731-5737.	1.6	63
72	Multidimensional fatigue and its correlates in hospitalised advanced cancer patients. European Journal of Cancer, 2007, 43, 1030-1036.	2.8	40

#	Article	IF	CITATIONS
73	The Effects of Analgesic Prescription and Patient Adherence on Pain in a Dutch Outpatient Cancer Population. Journal of Pain and Symptom Management, 2007, 34, 523-531.	1.2	61
74	Analgesic Adherence Measurement in Cancer Patients: Comparison Between Electronic Monitoring and Diary. Journal of Pain and Symptom Management, 2007, 34, 639-647.	1.2	24
75	Dying at home or in an institution: perspectives of Dutch physicians and bereaved relatives. Supportive Care in Cancer, 2007, 15, 1413-1421.	2.2	30
76	Skeletal Retention of Bisphosphonate (Pamidronate) and Its Relation to the Rate of Bone Resorption in Patients With Breast Cancer and Bone Metastases. Journal of Bone and Mineral Research, 2005, 20, 1543-1547.	2.8	43
77	Attitudes of Patients With Incurable Cancer Toward Medical Treatment in the Last Phase of Life. Journal of Clinical Oncology, 2005, 23, 2012-2019.	1.6	148
78	Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer, 2005, 50, 123-127.	2.0	90
79	Considerations of healthcare professionals in medical decision-making about treatment for clinical end-stage cancer patients. Journal of Pain and Symptom Management, 2004, 28, 351-355.	1.2	24
80	Nitrous oxide is not beneficial for breakthrough cancer pain. Palliative Medicine, 2002, 16, 257-259.	3.1	14
81	A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer, 2002, 94, 3049-3056.	4.1	67
82	Extracellular brain glutamate during acute liver failure and during acute hyperammonemia simulating acute liver failure. Journal of Hepatology, 1994, 20, 19-26.	3.7	83
83	Quantitative EEG analysis and evoked potentials to measure (latent) hepatic encephalopathy. Journal of Hepatology, 1992, 14, 141-142.	3.7	31
84	Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology, 1991, 100, 1114-1118.	1.3	93
85	Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit. Metabolic Brain Disease, 1990, 5, 131-141.	2.9	32
86	Objective measurement of hepatic encephalopathy in pigs by means of spectral analysis and evoked responses. Brain Research, 1985, 360, 298-303.	2.2	7
87	Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalography and Clinical Neurophysiology, 1984, 57, 423-426.	0.3	138